Preclinical Evaluation of Recombinant T Cell Receptor Ligand RTL1000 as a Therapeutic Agent in Ischemic Stroke

Translational Stroke Research

Volumn 6, Issue 1, 2015, Pages 60-68

  Zhu, Wenbin ^a   Casper, Amanda ^a   Libal, Nicole L ^a   Murphy, Stephanie J ^a   Bodhankar, Sheetal ^a,b   Offner, Halina ^a,b   Alkayed, Nabil J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

HLA DR2 transgenic mice; Immunotherapy; Ischemic stroke; Neurobehavioral evaluation; Recombinant T cell receptor ligand

Indexed keywords

LIGAND; NEUROPROTECTIVE AGENT; RECOMBINANT RECEPTOR; RECOMBINANT T CELL RECEPTOR LIGAND 1000; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; HYBRID PROTEIN; RECOMBINANT PROTEIN; RTL1000 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL BEHAVIORAL TEST; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OPEN FIELD TEST; PAW PREFERENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME; TREATMENT OUTCOME; ANIMAL; CEREBRAL ARTERY DISEASE; DRUG EFFECTS; MOTOR ACTIVITY; PATHOLOGY; STROKE; TRANSGENIC MOUSE;

ANIMALS; BRAIN ISCHEMIA; INFARCTION, MIDDLE CEREBRAL ARTERY; LIGANDS; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; STROKE; TREATMENT OUTCOME;

EID: 84921053967     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-014-0373-7     Document Type: Article

References (32)

1. Dirnagl U, Klehmet J, Braun JS, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke. 2007;38:770–3.
2. Muir KW, Tyrrell P, Sattar N, et al. Inflammation and ischemic stroke. Curr Opin Neurol. 2007;20:334–42.
3. Gee JM, Kalil A, Shea C, et al. Lymphocytes: potential mediators of postischemic injury and neuroprotection. Stroke. 2007;38(2 Suppl):783–8.
4. NilupulPerera M, Ma HK, Arakawa S, et al. Inflammation following stroke. J Clin Neurosci. 2006;13(1):1–8.
5. Hurn PD, Subramanian S, Parker SM, et al. T- and B-cell deficient mice with experimental stroke has reduced lesion size and inflammation. J Cereb Blood Flow Metab. 2007;27:1798–805.
6. Yilmza G, Arumugan TV, Stokes KY, et al. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006;113:2105–12.
7. Offner H, Subramanian S, Parker SM, et al. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006;26:654–65.
8. Offner H, Vandenbark AA, Hurn PD. Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience. 2009;158:1098–111.
9. Offner H, Subramanian S, Parker SM, et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176:6523–31.
10. Prass K, Meisel C, Hoflich C, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is medicated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198:725–36.
11. Burrows GG, Chang JW, Bachinger HP, et al. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng. 1999;12:771–8.
12. Wang C, Mooney JL, Meza-Romero R, et al. Recombinant TCR ligand induces early TCT signaling and a unique pattern of downstream activation. J Immunol. 2003;171:1934–40.
13. Vandenbark AA, Rich C, Mooney J, et al. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35–55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in DR2-TG transgenic mice. J Immunol. 2003;171:127–33.
14. Subramanian S, Zhang B, Kosaka Y, et al. Recombinant T cell receptor ligand treats experimental stroke. Stroke. 2009;40:2539–45.
15. Dziennis S, Mader S, Akiyoshi K, et al. Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice. Metab Brain Dis. 2011;26:123–33.
16. Yadav V, Dennis NB, Bowen JD, et al. Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis: a double-blind, placebo-controlled, phase I, dose-escalation study. Autoimmune Dis. 2012. doi:10.1155/2012/954739. Article ID: 954739.
17. Fisher M, Feuerstein G, David WH, et al. Update of stroke therapy academic industry rountable preclinical recommendations. Stroke. 2009;40:2244–50.
18. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752–58.
19. Gonzalez-Gay MA, Zanelli E, Khare SD, et al. Human leukocyte antigen-DRB1*1502 (DR2-TGDW12) transgene reduces incidence and severity of arthritis in mice. Hum Immunol. 1996;50:54–60.
20. Huan JY, Meza-Romero R, Mooney JL, et al. Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. J Chem Technol Biotechnol. 2005;80:2–12.
21. Zhu W, Wang L, Zhang L, et al. Isoflurane preconditioning neuroprotection in experimental focal stroke is androgen-dependent in male mice. Neuroscience. 2010;169:758–69.
22. Zhang W, Davis CM, Edin ML, et al. Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. PLoS One. 2013;8(4):e61244.
23. Uchida M, Palmateer JM, Herson PS, et al. Dose-dependent effects of androgens on outcome after focal cerebral ischemia in adult male mice. J Cereb Blood Flow Metab. 2009;29:1454–62.
24. Schallert T, Leasure JL, Kolb B. Experience-associated structural events, subependymal cellular proliferative activity, and functional recovery after injury to the central nervous system. J Cereb Blood Flow Metab. 2000;20:1513–28.
25. Craft TK, Zhang N, Glasper ER, et al. Neonatal factors influence adult stroke outcome. Psychoneuroendocrinology. 2006;31:601–13.
26. Li X, Blizzard KK, Zhu Z, et al. Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol. 2004;187:94–104.
27. Hammond RS, Tull LE, Stackman RW. On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem. 2004;82:26–34.
28. Akiyoshi K, Dziennis S, Palmateer J, et al. T cell receptor ligands improve outcome after experimental cerebral ischemia. Trans Stroke Res. 2011;2:404–10.
29. Vandenbark AA, Meza-Romero R, Benedek G, et al. A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. J Autoimm. 2013;40C:96–110.
30. Ren X, Akiyoshi K, Grafe MR, et al. Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity. Metab Brain Dis. 2012;27:7–15.
31. Benedek G, Meza-Romero R, Andrew S, et al. Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects. Eur J Immunol. 2013;43:1309–21.
32. Wang C, Gold BG, Kaler LJ, et al. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem. 2006;98:1817–27.